GlassScriptPhysician profile
Susan Lawton
NPI 1659390110
$5,024.62
in general payments reported to CMS, 2019-2025
24 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,207 · 2020: $434 · 2021: $556 · 2022: $726 · 2023: $1,495 · 2024: $498 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,102.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $777.72 | 2019-2024 | Biktarvy, Descovy |
| Amgen INC. | $536.18 | 2019-2024 | Prolia, Evenity |
| Lilly USA, LLC | $485.54 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $412.04 | 2019-2024 | Bexsero, Pediarix, Rotarix |
| Pfizer INC. | $402.31 | 2019-2024 | |
| Novo Nordisk INC | $385.68 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $271.56 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $222.80 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Genzyme Corporation | $216.45 | 2023 | |
| Abbvie INC. | $207.76 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $197.60 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $164.54 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $162.28 | 2019-2022 | |
| Organon LLC | $105.83 | 2021-2022 | |
| Viiv Healthcare Company | $103.00 | 2023 | Apretude |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.64 | 2021-2022 | |
| Sanofi Pasteur INC. | $71.90 | 2022-2023 | |
| Exact Sciences Corporation | $71.86 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $40.84 | 2021 | |
| Dexcom, INC. | $22.78 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $21.16 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.92 | 2019 | |
| Coopersurgical, INC. | $17.88 | 2023 | Paragard T 380a |
| Evofem Biosciences, INC. | $14.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Lawton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.